Clinical Presentation and Natural History of Graves’ Ophthalmopathy

  • P. Perros
  • A. J. Dickinson
  • P. Kendall-Taylor
Chapter
Part of the Endocrine Updates book series (ENDO, volume 14)

Abstract

Graves’ ophthalmopathy (GO) is clinically apparent in about 35% patients with Graves’ disease, but is subclinically present in most patients (8). The presentation of GO is highly variable. None of the clinical signs of GO are pathognomonic, yet this condition is rarely a diagnostic challenge to the experienced clinician. However delays in making the diagnosis by nonspecialists is common. Clinicians managing patients with GO have to decide which aspects of a patient’s presentation warrant referral to a specialist centre. The clinical course of GO through time is multiphasic and spontaneous regression occurs in most patients. The “natural history” of this disease is a concept of critical importance in prognosis, and timing of therapeutic interventions.

Keywords

Optic Neuropathy Extraocular Muscle Radioiodine Therapy Relative Afferent Pupillary Defect Clinical Activity Score 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bahn RS, Bartley GB, Gorman CA. Emergency treatment of Graves’ ophthalmopathy. Baillieres Clin Endocrinol Metab. 1992; 6:95–105.PubMedCrossRefGoogle Scholar
  2. 2.
    Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell’Unto E, et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med 1998; 338:73–78.PubMedCrossRefGoogle Scholar
  3. 3.
    Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A. Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med. 1989; 321:1349–52PubMedCrossRefGoogle Scholar
  4. 4.
    Bartalena L, Martino E, Marcocci C, Bogazzi E, Panicucci M, Velluzzi F et al. More on smoking habits and Graves’ ophthalmopathy. Journal of Endocrinological Investigation 1989; 12:733–737.PubMedGoogle Scholar
  5. 5.
    Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev. 2000; 21:168–99.PubMedCrossRefGoogle Scholar
  6. 6.
    Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, Gorman CA. Long term follow-up of Graves’ ophthalmopathy in an incidence cohort. Ophthalmology 1996; 103:958–962.PubMedGoogle Scholar
  7. 7.
    Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JAet al. Clinicalfeatures of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996; 121:284–290.PubMedGoogle Scholar
  8. 8.
    Burch HB, Wartofsky L. Graves’ ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 1993; 14:747–793.PubMedGoogle Scholar
  9. 9.
    Catz B & Pernik SL. Total thyroidectomy in the management of thyrotoxic and euthyroid Graves’ disease. Am J Surg. 1969. 118.434–439PubMedCrossRefGoogle Scholar
  10. 10.
    Char I. Superior limbic keratoconjunctivitis: multifactorial mechanical pathogenesis. Clin Experiment Ophthalmol. 2000; 28:181–4.CrossRefGoogle Scholar
  11. 11.
    Cole M, Mitchell S, Paisey R. Yeldham D. Recognising and treating thyroid-associated ophthalmopathy. Practitioner. 1995; 239:261–3.PubMedGoogle Scholar
  12. 12.
    DeGroot LJ, Gorman CA, Pinchera A, Bartalena L, Marcocci C, Wiersinga WM, Prummel MF, Wartofsky L, Marocci C. Therapeutic controversies. Retro-orbital radiation and radioactive iodide ablation of the thyroid may be good for Graves’ ophthalmopathy. J Clin Endocrinol Metab. 1995; 80:339–40.CrossRefGoogle Scholar
  13. 13.
    Fells P, Kousoulides L, Pappa A, Munro P, Lawson J. Extraocular muscle problems in thyroid eye disease. Eye. 1994; 8:497–505.PubMedCrossRefGoogle Scholar
  14. 14.
    Garrity JA, Fatourechi V, Bergstrahl EJ, Bartley GB, Beatty CW, DeSanto LWet al.Results of transantral orbital decompression in 428 patients with severe Graves’ ophthalmopathy. Am J Ophthalmol 1993; 116:533–547.PubMedGoogle Scholar
  15. 15.
    Gerding MN, Prummel MF, Wiersinga WM. Assessment of disease activity in Graves’ ophthalmopathy by orbital ultrasonography and clinical parameters. Clin Endocrinol (Oxf). 2000; 52:641–6.CrossRefGoogle Scholar
  16. 16.
    Gerding MN, van der Meer JW, Broenink M, Bakker 0, Wiersinga WM, Prummel MF. Association of thyrotrophin receptor antibodies with the clinical features of Graves’ ophthalmopathy. Clin Endocrinol 2000; 52:267–71CrossRefGoogle Scholar
  17. 17.
    Gorman C. Radioiodine therapy does not aggravate Graves’ ophthalmopathy. J Clin Endocrinol Metab 1995; 80:340–2.Google Scholar
  18. 18.
    Gorman CA, Offord K. Therapy for hyperthyroidism and Graves’ Ophthalmopathy. N Eng J Med. 1998; 338:1546.CrossRefGoogle Scholar
  19. 19.
    Gorman CA. Temporal relationship between onset of Graves’ ophthalmopathy and diagnosis of thyrotoxicosis. Mayo Clin Proc. 1983; 58:515–9.PubMedGoogle Scholar
  20. 20.
    Gruters A. Ocular manifestations in children and adolescents with thyrotoxicosis. Exp Clin Endocrinol Diabetes 1999; 107:5172–4.CrossRefGoogle Scholar
  21. 21.
    Hagg E, Asplund K. Is endocrine opthalmopathy related to smoking? Br Med J 1987; 295:634–635.CrossRefGoogle Scholar
  22. 22.
    Hales IB and Rundle FF. Ocular changes in Graves’ Disease. Quart J Med 1960; 29:113–126.PubMedGoogle Scholar
  23. 23.
    Heufelder AE, Spitzweg C. Immunology of Graves’ ophthalmopathy. Dev Ophthalmol. 1999; 30:24–38.PubMedCrossRefGoogle Scholar
  24. 24.
    Heward JM, Allahabadia A, Armitage M, Hattersley A, Dodson PM, Macleod K, Carr-Smith J, Daykin J, Daly A, Sheppard MC, Holder RL, Barnett AH, Franklyn JA, Gough SC The development of Graves’ disease and the CTLA-4 gene on chromosome 2q33. J Clin Endocrinol Metab 1999; 84:2398–401PubMedCrossRefGoogle Scholar
  25. 25.
    Kadrmas EF, Bartley GB. Superior limbic keratoconjunctivitis. A prognostic sign for severe Graves ophthalmopathy. Ophthalmology. 1995;102:1472–5.PubMedGoogle Scholar
  26. 26.
    Karlsson AF, Westermark K, Dahlberg PA, Jansson R, Enoksson P. Ophthalmopathy and thyroid stimulation. Lancet.1989; 2:691PubMedCrossRefGoogle Scholar
  27. 27.
    Kendall-Taylor P, Perros P. Clinical presentation of thyroid associated orbitopathy. Thyroid. 1998; 8(5):427–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Kendler DL, Lippa J, Rootman J. The initial clinical sharacteristics of Graves’ orbitopathy with age and sex. Arch Ophthalmol. 1993. 111: 197–201PubMedCrossRefGoogle Scholar
  29. 29.
    Kung AEC, Yau CC Cheng A. The incidence of ophthalmopathy after radioiodine therapy for Graves’ disease: prognostic factors and the role of methimazole. J Clin Endocrinol. Metab. 1994. 79. 542–546PubMedCrossRefGoogle Scholar
  30. 30.
    Lazarus JH. Relation between thyroid eye disease and type of treatment of Graves’ hyperthyroidism. Thyroid. 1998; 8:437.PubMedCrossRefGoogle Scholar
  31. 31.
    Mann K. Risk of smoking in thyroid-associated orbitopathy Exp Clin Endocrinol Diabetes 1999; 107 Suppl 5:S164–7CrossRefGoogle Scholar
  32. 32.
    Manso PG, Furlanetto RP, Wolosker AMB, Paiva ER, de Abreu MT, Maciel RMB. Prospective and controlled study of ophthalmopathy after radioiodine therapy for Graves’ hyperthyroidism. Thyroid 1998; 8:49–52.PubMedCrossRefGoogle Scholar
  33. 33.
    Marcocci C, Bartalena L, Bogazzi F, Panicucci M, Pinchera A. Studies on the occurrence of ophthalmopathy in Graves’ disease. Acta Endocrinol (Copenh). 1989; 120:473–8.Google Scholar
  34. 34.
    Marcocci C, Bruno-Bossio G, Manetti L, Tanda ML, Miccoli P, Iacconi P, Bartolomei MP, Nardi M, Pinchera A, Bartalena L. The course of Graves’ ophthalmopathy is not influenced by near total thyroidectomy: a case-control study. Clin Endocrinol (Oxf). 1999; 51:503–8.CrossRefGoogle Scholar
  35. 35.
    Marino M, Barbesino G, Pinchera A, Manetti L, Ricciardi R, Rossi B, Muratorio A, Braverman LE, Mariotti S, Chiovato L. Increased frequency of euthyroid ophthalmopathy in patients with Graves’ disease associated with myasthenia gravis. Thyroid. 2000; 10(9):799–802.PubMedCrossRefGoogle Scholar
  36. 36.
    McKinnon SG, Gentry LR. Systemic diseases involving the orbit. Semin Ultrasound CT MR. 1998; 19(3):292–308.PubMedCrossRefGoogle Scholar
  37. 37.
    Mourits MP, Prummel MF, Wiersinga WM, Koomneef L. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol 1997; 47:9–14.CrossRefGoogle Scholar
  38. 38.
    Perros P, Crombie AL, Kendall-Taylor P. Natural history of thyroid associated ophthalmopathy. Clin Endocrinol 1995; 42:45–50.CrossRefGoogle Scholar
  39. 39.
    Pinchera A, Wiersinga W, Glinoer D, Kendall-Taylor P, Koornneef L, Marcocci Cet al.Classification of eye changes of Graves’ disease. Thyroid 1992; 2:235–236.CrossRefGoogle Scholar
  40. 40.
    Prummel MF, Wiersinga WM, Mourits MPh, Koorneef L, Berghout A & van der Gaag R. Effects of abnormal thyroid function on the severity of Graves’ ophthalmopathy. Arch Int Med. 1990 150 1098–1011CrossRefGoogle Scholar
  41. 41.
    Rundle FF. Development and course of exophthalmos in Graves’ disease with special reference to the effect of thyroidectomy. Clinical Science 1945; 5: 177PubMedGoogle Scholar
  42. 42.
    Scott IU, Siatkowski MR. Thyroid eye disease. Semin Ophthalmol. 1999; 14(2):5261.PubMedCrossRefGoogle Scholar
  43. 43.
    Solem JH, Segaard E and Ytteborg J. The course of endocrine ophthalmopathy during antithyroid therapy in a prospective study. Acta Med Scand 1979; 205:111–114.PubMedCrossRefGoogle Scholar
  44. 44.
    Streeten DHP, Anderson GH, Reed GF and Woo P. Prevalence, natural history and surgical treatment of exophthalmos. Clin Endocrin 1987; 27:125–133.CrossRefGoogle Scholar
  45. 45.
    Tallstedt L, Lundell G, Blomgren H, Bring J. Does early administration of thyroxine reduce the development of Graves’ ophthalmopathy after radioiodine treatment? Eur J Endocrinol. 1994; 130:494–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, Taube A. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. The Thyroid Study Group. N Engl J Med. 1992; 326:1733–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Tallstedt L, Lundell G. Radioiodine treatment, ablation, and ophthalmopathy: a balanced perspective. Thyroid. 1997; 7:241–5.PubMedCrossRefGoogle Scholar
  48. 48.
    Tallstedt L. Surgical treatment of thyroid eye disease. Thyroid 1998; 8:447–452.PubMedCrossRefGoogle Scholar
  49. 49.
    Terwee CB, Wakelkamp IMMJ, Tan HS, Dekker FW, Prummel MF, Wiersinga WM. Long-term effects of Graves’ ophthalmopathy on health-related quality of life. 2001. SubmittedGoogle Scholar
  50. 50.
    Trobe JD, Glaser JS, Laflamme P. Dysthyroid optic neuropathy. Clinical profile and rationale for management. Arch Ophthalmol. 1978; 96(7):1199–1209.PubMedCrossRefGoogle Scholar
  51. 51.
    Vaidya B, Imrie H, Perros P, Dickinson J, McCarthy MI, Kendall-Taylor Pet al.CytotoxicT-lymphocyte antigen-4 (CTLA-4) gene polymorphism confers susceptibility to thyroid associated orbitopathy. Lancet 1999; 354:743–744.PubMedCrossRefGoogle Scholar
  52. 52.
    Vaidya B, Imrie H, Perros P, Young ET, Kelly WF, Carr Det al.The cytotoxic T lymphocyte antigen-4 is a major Graves’ disease locus. Hum Mol Genet 1999; 8:1195–1199.PubMedCrossRefGoogle Scholar
  53. 53.
    Weetman AP, Harrison BJ. Ablative or non-ablative therapy for Graves’ hyperthyroidism in patients with ophthalmopathy? J Endocrinol Invest. 1998; 21:4725.Google Scholar
  54. 54.
    Weetman AP. Medical Progress: Graves’ Disease. N Engl J Med. 2000; 343:1236–1248.PubMedCrossRefGoogle Scholar
  55. 55.
    Wiersinga WM, Prummel MF. An evidence-based approach to the treatment of Graves’ ophthalmopathy. Endocrinol Metab Clin North Am. 2000; 29:297–319.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • P. Perros
    • 1
  • A. J. Dickinson
    • 1
  • P. Kendall-Taylor
    • 1
  1. 1.Departments of Medicine and OphthalmologyUniversity of Newcastle on TyneUSA

Personalised recommendations